Optimized hemophilia care requires rapid, accurate, and high-quality genetic testing, but access to these tests varies across the European Union, according to a recent study.
Equitable access to genetic testing for hemophilia across Europe varies and needs to be improved, according to the authors of a recent analysis.
Writing in Haemophilia, the researchers, located in Belgium, said they wanted information about accessible, online laboratory facilities in the European Union (EU) for genetic hemophilia testing, including the laboratories’ performance in updating data, quality control, variants analyzed, techniques used, turnaround time (TAT), and costs.
Specifically, they were interested in the spectrum of variants in the F8 (Xq28) or F9 (Xq27.1) genes, both located on the X chromosome.
“Genetic assessment of haemophilia is paramount to investigating disease biology, establishing diagnosis in difficult cases, predicting the risk of inhibitor development, and identifying female carriers, in addition to enabling prenatal diagnosis,” the authors wrote, adding that for stakeholders, it is important “that resources able to centralize information on genetic tests for haemophilia within a standardized environment be made available.”
They cited 2 international genetic databases, which they used in their analysis, in order to find more specific information about what is available in EU countries. One is Orphanet and another is the NCBI Genetic Testing Registry. They also collected and analyzed data from laboratory websites, PubMed, and government organizations.
The authors excluded laboratories that did not have a website, did not have a website with a translated version in English, did not mention molecular analyses, did not include the analysis of 1 of the 2 hemophilia genes, or had no recent update in the major international databases.
The analysis included 51 genetic laboratories across 15 European countries with recently updated molecular testing for hemophilia; most of the laboratories provided gene sequencing for small variants of both F8 and F9 genes.
“Almost two-thirds of them offer analysis for inversions using a polymerase chain reaction method and detection of copy number variation using multiplex ligation-dependent probe amplification (MLPA),” the researchers wrote.
Few laboratories provided costs. Of those that did, they ranged from 121€ to 508.76€ for F8 and from 135€ to 1793.6€ for inversions. The variation for F9 was similar.
For TAT, half of the labs provided estimates, but since those methods lacked standardization, understanding the true time to get results was difficult to interpret. Some laboratories established the TAT by business days, days, weeks, or months, and times varied from 1 to 2 weeks to 60 days for inversion analysis results, 15 to 120 working days for sequencing/MLPA results, and up to 4 to 6 months for all results.
Almost three-quarters of laboratories showed a last modified date or change history, which is “considered a guarantee of the test’s reliability in a domain where technologies and resources rapidly evolve.” Similarly, most facilities held an ISO 15189 standard accreditation for genetic laboratories, but only a few participated in external quality assessment.
Notably, labs in Eastern European countries lagged the most, the analysis found. Overall, across the EU, finding data “is still difficult and time consuming.”
Reference
Lannoy N, Hermans C. Accessibility and visibility of genetic testing for haemophilia across Europe: where do we stand? Haemophilia. Published online October 12, 2022. doi:10.1111/hae.14672
Enhancing Outpatient Hemophilia Care May Improve Health Outcomes and Costs
May 18th 2024Prospective data from patients attending a rural practice in West Virginia between 2016 and 2023 show that a quality improvement program that followed guideline recommendations and was tailored to specific patient needs reduced preventable bleeds and lowered costs.
Read More
Bleeds and Resource Use in Hemophilia B: Retrospective Observational Study
May 15th 2024This real-world US study describes individuals with hemophilia B who experience bleeds despite factor replacement therapy and quantifies the associated comorbidity and health care resource utilization burden.
Read More
Health Equity, Accessibility Essential to Supporting Women Affected by Hemophilia
May 10th 2024Due to often being overlooked as only carriers of hemophilia, the review authors sought to highlight the needs of female caretakers for patients with the disorder and the possibility of women themselves being affected by it.
Read More
Coexistence of HIV, Hemophilia May Lead to Increased Presence of Coronary Artery Stenosis
May 8th 2024In patients living with HIV, the cardiovascular risk factors that come with infection may lead to an increased prevalence of coronary artery stenosis, especially in those who also have hemophilia.
Read More
Review: One-Shot Etranacogene Dezaparvovec Represents Game-Changing Gene Therapy for Hemophilia B
May 3rd 2024More than 20 years of gene therapy clinical research have led to etranacogene dezaparvovec’s use in hemophilia B, according to authors of a recent review—and it takes its place in a line of current and potentially many future genomic medicines for a range of diseases.
Read More